Ozempic/Mounjaro: Why They Fail Some Diabetics?

Medications such as Ozempic and Mounjaro have revolutionized Type 2 diabetes and obesity treatment, yet their effectiveness differs among patients. Approximately 10-15% of individuals see only minor benefits, prompting questions about this variability. The differing responses are primarily due to individual biological differences.

These drugs mimic gut hormones, activating GLP-1 and GIP pathways to regulate metabolism, improve insulin release, and reduce appetite. However, genetic variations affecting hormone receptors or leading to GLP-1 resistance can diminish their impact. Factors like diabetes duration, pancreatic function, and visceral fat also play significant roles.

When treatment seems ineffective, a comprehensive reassessment is vital. Clinicians review adherence, dosage, and timing before considering adjustments. Combining these medications with others or increasing the dose can improve outcomes for some. Emphasis is placed on personalized therapy, considering a patient's overall health profile.

Crucially, dramatic weight loss achieved in trials for these medications was a result of combined efforts. Participants adhered to calorie-restricted diets and increased physical activity alongside taking the medication. Therefore, sustained lifestyle modifications, including a balanced diet, regular exercise, adequate sleep, and stress management, remain fundamental to successful diabetes and obesity management.